EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

Matthew Davis, William Towner iD, Elliot DeHaan iD, Qin Jiang iD, Wen Li, Farah Rahman iD, Michael Patton, Hayley Wyper, Maria Maddalena Lino, Uzma N Sarwar iD, Zaynah Majid-Mahomed iD, Saumil Mehta und 9 weitere

Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 911-920

DOI: 10.1093/cid/ciae550 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.11.2024. Verfasst von Matthew Davis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Rochester Clinical Research, Inc., Rochester, New York, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older individuals and adults with certain chronic or immunocompromising health conditions are at increased risk of severe respiratory syncytial virus (RSV) disease.

Methods

In this phase 3 randomized trial of RSVpreF safety and immunogenicity in 18–59-year-olds at high risk of severe RSV disease, participants were randomized 2:1 to 1 RSVpreF (120 µg) or placebo dose. Primary safety endpoints included reactogenicity events and adverse events (AEs) through 7 days and 1 month after vaccination, respectively, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) throughout the study. In primary analyses, immunogenicity elicited 1 month after RSVpreF was bridged to a randomly selected subset of ≥60-year-olds receiving RSVpreF from the immunogenicity subset in the pivotal phase 3 RENOIR trial, which demonstrated RSVpreF efficacy. Noninferiority was declared if 95% confidence interval (CI) lower bounds were >.667 (neutralizing titer adjusted geometric mean ratios) and >−10% (seroresponse rate differences) for RSV-A and RSV-B.

Results

Overall, 678 participants received RSVpreF (n = 453) or placebo (n = 225). Most reactogenicity events were mild/moderate; severe events occurred in ≤2.0% of participants overall. AE frequencies were similar in RSVpreF (7.1%) and placebo recipients (7.6%). No vaccine-related SAEs or NDCMCs were reported. One month after RSVpreF administration, noninferiority criteria were met in 18–59-year-olds versus ≥60-year-olds for RSV-A and RSV-B neutralizing titers and seroresponse rates.

Conclusions

RSVpreF was well tolerated with no safety concerns and demonstrated immunobridging to efficacy in 18–59-year-olds at high risk of severe RSV disease versus ≥60-year-olds in whom efficacy was previously demonstrated, supporting use of RSVpreF to prevent RSV-associated disease in this population. NCT05842967.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAntibodies, NeutralizingAntibodies, ViralImmunogenicity, VaccineRespiratory Syncytial Virus, Human

Stichwörter der Autor:innen

RSVRSVpreFimmunogenicitysafetyvaccine

Substanzen

Antibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Rochester Clinical Research, Inc., Rochester, New York, USA.
  • Kaiser Permanente Southern California, Los Angeles, California, USA.
  • Vaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.
  • Vaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Vaccine Research & Development, Pfizer Ltd, Marlow, United Kingdom.
  • AIM Trials, Plano, Texas, USA.

ORCID-Profile: William Towner, Elliot DeHaan, Qin Jiang, Farah Rahman, Uzma N Sarwar, Zaynah Majid-Mahomed

Förderung

  • Pfizer

Zitieren

APA

Davis, M., Towner, W., DeHaan, E., Jiang, Q., Li, W., Rahman, F., Patton, M., Wyper, H., Lino, M. M., Sarwar, U. N., Majid-Mahomed, Z., Mehta, S., Howitt, W., Cannon, K., Kalinina, E., Cooper, D., Swanson, K. A., Anderson, A. S., Gurtman, A., …, & MONeT Study Team (2025). Bivalent RSVpreF Vaccine in Adults 18 to. Clinical Infectious Diseases, 80(4), 911-920. https://doi.org/10.1093/cid/ciae550

Vancouver

Davis M, Towner W, DeHaan E, Jiang Q, Li W, Rahman F, et al. Bivalent RSVpreF Vaccine in Adults 18 to. Clinical Infectious Diseases. 2025;80(4):911-920. doi:10.1093/cid/ciae550

BibTeX
@article{Davis2025,
  author = {Davis, Matthew and Towner, William and DeHaan, Elliot and Jiang, Qin and Li, Wen and Rahman, Farah and Patton, Michael and Wyper, Hayley and Lino, Maria Maddalena and Sarwar, Uzma N and Majid-Mahomed, Zaynah and Mehta, Saumil and Howitt, William and Cannon, Kevin and Kalinina, Elena and Cooper, David and Swanson, Kena A and Anderson, Annaliesa S and Gurtman, Alejandra and Munjal, Iona and MONeT Study Team, MONeT Study Team},
  title = {Bivalent RSVpreF Vaccine in Adults 18 to},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {911--920},
  doi = {10.1093/cid/ciae550}
}
Kostenlos starten →